Cost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthma

Journal of Asthma

Volumn 53, Issue 2, 2016, Pages 194-200

  Zein, Joe G ^a   Menegay, Michelle C ^b   Singer, Mendel E ^b   Erzurum, Serpil C ^a   Gildea, Thomas R ^a   Cicenia, Joseph C ^a   Khatri, Sumita ^a   Castro, Mario ^c   Udeh, Belinda L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Cost; Effectiveness; Thermoplasty

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHIAL THERMOPLASTY; BRONCHOSCOPY; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; HEALTH CARE COST; HIDDEN MARKOV MODEL; HOSPITALIZATION COST; HUMAN; MEDICARE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TRACHEOBRONCHIAL TREE; COST BENEFIT ANALYSIS; ECONOMICS; PULSED RADIOFREQUENCY TREATMENT;

ADULT; ASTHMA; COST-BENEFIT ANALYSIS; HUMANS; PULSED RADIOFREQUENCY TREATMENT;

EID: 84941662789     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2015.1072552     Document Type: Article

References (36)

1. CDC. Asthma. 2013. Available from: http://www.Cdc.Gov/asthma/[last accessed 5 Aug 2014]
2. Nih. Asthma info. 2013. Available from: http://www.Nhlbi.Nih.Gov/health-pro/resources/lung/naci/asthma-info/[last aaccessed 4 Aug 2014]
3. Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24: 659-663
4. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, et al., Group AIRTS. Asthma control during the year after bronchial thermoplasty. New Engl J Med 2007; 356: 1327-1337
5. Torrego A, Sola I, Munoz AM, Roque IFM, Yepes-Nunez JJ, Alonso-Coello P, Plaza V. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev 2014; 3: CD009910
6. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, Chung KF, Laviolette M, Group RTS. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007; 176: 1185-1191
7. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, et al., Group AIRTS. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181: 116-124
8. Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, et al., Asthma Intervention Research 2 Trial Study G. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013; 132: 1295-1302
9. Cangelosi MJ, Ortendahl JD, Meckley LM, Bentley TG, Anene AM, Shriner KM, Fox J. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Expert Rev Pharmacoeconom Outcomes Res 2015; 15: 357-364
10. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1339-1341
11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258
12. Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, Krishnan JA. Mortality in patients hospitalized for asthma exacerbations in the united states. Am J Respir Crit Care Med 2006; 174: 633-638
13. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83
14. The Healthcare Cost and Utilization Project (HCUP). Available from: http://www.hcup-us.ahrq.gov [last accessed 12 Jul 2014]
15. MM7443-Centers for Medicare & Medicaid Services; July 1 AfhwcgO-a-EM-L-N-MMdmp
16. The Consumer Price Index program-Bureau of Labor Statistics. Available from: http://www.bls.gov/cpi/[last accessed 12 Jul]
17. Center for the Evaluation of Value and Risk in Health. The cost-effectiveness analysis registry. Boston: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: www.cearegistry.org [last accessed 5 Jul 2014]
18. Allegra L, Cremonesi G, Girbino G, Ingrassia E, Marsico S, Nicolini G, Terzano C, Group PS. Real-life prospective study on asthma control in italy: cross-sectional phase results. Respir Med 2012; 106: 205-214
19. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, Bateman ED, Group GI. Cost-effectiveness of asthma control: an economic appraisal of the goal study. Allergy 2006; 61: 531-536
20. Steuten L, Palmer S, Vrijhoef B, van Merode F, Spreeuwenberg C, Severens H. Cost-utility of a disease management program for patients with asthma. Int J Technol Assess Health Care 2007; 23: 184-191
21. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010; 65: 1141-1148
22. Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004; 13: 113-4
23. Tsuchiya A BJ, McColl E, Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices. 2002. Available from: http://eprints.whiterose.ac.uk/10952/1/HEDS-DP-02-01.pdf [last accessed 15 Jul 2014]
24. CDC-Division of Vital Statistics-National Center for Health Statistics. Available from: http://www.cdc.gov/nchs/nvss/mortality-tables.htm [last accessed on 15 Jul 2014]
25. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-qaly threshold. New Engl J Med 2014; 371: 796-797
26. Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the united states: evidence from the medical expenditure panel survey. J Allergy Clin Immunol 2011; 127: 363-369, e361-363
27. World Health Organization-Cost-effectiveness threaholds. Available from: http://www.who.int/choice/costs/CER-thresholds/en/[last accessed 19 Jul 2014]
28. Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001; 108: 39-46
29. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmaco Economics 2007; 25: 577-590
30. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156: 787-793
31. Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999; 160: 211-215
32. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the united states. New Engl J Med 1992; 326: 862-866
33. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J Allergy Clin Immunol 2007; 120: 1146-1152
34. Barrett ML, Wier LM, WashingtonR. Healthcare Cost and Utilization Project (HCUP); trends in pediatric and adult hospital stays for asthma, 2000-2010. January 2014. Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb169-Asthma-Trends-Hospital-Stays.jsp [last accessed 12 Aug 2014]
35. Merrill CT, Stranges E, Steiner C. Hospital stays related to asthma for adults, 2005: statistical brief #54. Healthcare cost and utilization project (hcup) statistical briefs. Rockville (MD); 2006
36. O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. PharmacoEconomics 2004; 22: 815-825